Aubagio (Teriflunomide) Patent Expiration, LOE Window & CMS Spending
Aubagio (Teriflunomide) by Sanofi: FDA Orange Book LOE 2034-08-04, 13 AB generics, $170.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sanofi |
| FDA Application & Pathway | N202992 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2034-08-04 |
| Orange Book Patents (*PED Extensions) | 6 patents (3 *PED) |
| Active AB-Rated Generic Competitors | 13 |
| 2024 CMS Total Public Spend | $170.7M |
| 2024 Medicare Part D Spend | $148.5M |
| 2024 Medicaid Spend | $22.2M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 21.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.